HCW Biologics Inc. HCWB
Regular-session close
After hours · Nov 19, 5:06 PM ET
- YTD
- -87.39%
- 1 year
- -93.87%
5D -0.1592 (-16.60%)
- Market cap
- 2.31M
- Revenue (ttm)
- 3.92M
- EPS (ttm)
- -19.84
- Shares out
- 44.54M
- Forward P/E
- -0.73
- YTD return
- -87.39%
- 1-year return
- -93.87%
- 50-day average
- 0.4952
- Volume
- 17.17K
- Avg volume
- 381.02K
- Open
- 0.761
- Previous close
- 0.7639
- Day's range
- 0.7351 – 0.784
- 52-week range
- 0.7351 – 23.94
- Beta
- 0.84
- Price target
- 3.00 (+308.1%)
Key statistics
- 200-day average
- 0.83988
- Enterprise value
- 20.01M
- Price / sales
- 4.53
- Price / book
- 1.07
- Revenue growth
- -0.60%
- Free cash flow
- -6.03M
- Total cash
- 1.16M
- Total debt
- 10.02M
- Return on equity
- -344.32%
- Short % of float
- 0.04%
Fundamental scorecard
6 of 25 checks passed on HCWB’s reported financials
6of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 1 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.10 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.40 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.20 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.30 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.14 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -0.12 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 19, 2023 | EF Hutton | reit | — | Buy |
| Mar 30, 2023 | EF Hutton | reit | — | Buy |
| Mar 23, 2023 | EF Hutton | reit | — | Buy |
| Nov 8, 2022 | JonesTrading | init | — | Buy |
| Mar 24, 2022 | Maxim Group | init | — | Buy |
| Nov 19, 2021 | EF Hutton | init | — | Buy |
About HCW Biologics Inc.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- hcwbiologics.com
News
HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics' Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company's Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer's 41st Annual Meeting HCW Biologics Announces It Secured $10M In Cash To Finance Its Phase 1 Trial Of HCW9302 To Treat Alopecia Areata
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
HCW Biologics Inc. (NASDAQ:HCWB) Shares Shorted: Short Interest Up 557.1% in September
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
HCW Biologics Announces Pricing of $1.5 Million Private Placement
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
Your note
Sign in to keep a note on HCWB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BYAM REBECCA | Chief Financial Officer | Stock Award(Grant) | Feb 19, 2024 | 1,381,910 |
| FLOWERS LEE | Officer | Stock Award(Grant) | Feb 19, 2024 | 190,238 |
| GARRETT SCOTT T | Director | Stock Award(Grant) | Feb 19, 2024 | 0 |
| GILES LISA M | Director | Stock Award(Grant) | Feb 19, 2024 | 35,815 |
| GREENE RICK SCOTT | Director | Stock Award(Grant) | Feb 19, 2024 | 44,125 |
| RHODE PETER | Officer | Conversion of Exercise of derivative security | Dec 10, 2023 | 77,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Avantax Planning Partners, Inc. | 0.74% | 279,541 | 111.48K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.48% | 183,259 | 73.08K | Sep 29, 2024 |
| HighTower Advisors, LLC | 0.48% | 180,810 | 72.11K | Sep 29, 2024 |
| Cresset Asset Management, LLC | 0.35% | 131,990 | 52.64K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.22% | 84,700 | 33.78K | Sep 29, 2024 |
| Pullen Investment Management, LLC | 0.20% | 75,116 | 29.96K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.25% | 95,207 | 37.97K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 84,700 | 33.78K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.11% | 40,685 | 16.23K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.10% | 37,677 | 15.03K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 29,023 | 11.57K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 22,600 | 9.01K | Oct 30, 2024 |
